Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA™ (Ceftolozane and Tazobactam)
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Committee for Medicinal Products for Human Use
(CHMP) of the European Medicines Agency (EMA) has adopted a positive
opinion recommending approval of the investigational antibiotic ZERBAXAâ„¢
(ceftolozane and tazobactam) for the treatment of the following
infections in adults: complicated intra-abdominal infections, acute
pyelonephritis, and complicated urinary tract infections.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558orRobert Consalvo, 908-236-1127orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Prescription Medicine News Corporate News Latest News Source Type: news
More News: European Medicines Agency (EMA) | Merck | Pharmaceuticals | Pyelonephritis | Urinary Tract Infections